Introduction
Immune-mediated disorders often present as a combination of destructive tissue damage and variable systemic organ manifestations based on an overwhelming T-and/or B-cell reaction. There has been great interest recently in targeting the interleukin-2 (IL-2) pathway by specific immunosuppressive drugs and the use of CD4 ϩ CD25 ϩ Foxp3 ϩ regulatory T cells (Tregs) for the treatment of such inflammatory conditions. 1, 2 To specifically modulate aberrant immune responses such as acute graft-versus-host disease (aGVHD), allograft rejection, or autoimmune disorders by immunosuppressive therapy, while sparing Treg activity, a more detailed insight into the biologic differences between Tconv and Tregs is crucial. One critical requirement for Treg function and expansion in preventing aGVHD is calcineurin-dependent IL-2 production, 3 which is affected by the immunosuppressant cyclosporin A (CSA). In light of the finding that the interaction between NFATc and Foxp3 is required for the suppressive effects of Treg cell 4, 5 interference with nuclear factor of activated T cells (NFAT) by CSA may also contribute to the observed effects of CSA on Treg biology. We and others have shown that rapamycin (RAPA) but not CSA allows for Treg expansion and function in mice 3, 6, 7 and in humans. 8, 9 In contrast to CSA, RAPA inhibits mammalian target of rapamycin (mTOR) pathway activity, which is downstream of IL-2/phosphatidylinositol 3-kinase (PI3K) signaling. 10 This pathway is negatively regulated by PTEN (phosphatase and tensin homolog deleted on chromosome 10), a phosphoinositol 3,4,5-triphosphatase that catalyzes the reverse reaction of PI3K. 11 Other pathways that are activated in response to IL-2 signaling that may be preferentially used when mTOR is inhibited include the Janus tyrosine kinase (JAK)/signal transducer and activator of transcription (STAT) and the mitogen-activated protein kinase (MAPK) pathway. Recent data have demonstrated an essential role for IL-2 receptor (R)␤-dependent STAT5 signaling for the development of Tregs. 12 Here we describe the in vivo impact of mTOR inhibition on expansion, migration, Foxp3 expression, and activity of Tregs after allogeneic hematopoietic cell transplantation (aHCT). From a mechanistic standpoint, we studied the differential impact of RAPA on Tconv and Tregs with respect to PI3K/mTOR and STAT5 pathway activity.
Only sex-matched combinations were used for transplant experiments. The luciferase-expressing (luc ϩ ) transgenic FVB/N L2G85 were described previously 13 and backcrossed for more than 10 generations to the C57BL/6 background. All animal protocols were approved by the University Committee on Use and Care of Laboratory Animals at Stanford University.
Flow cytometric analysis
The following antibodies were used for flow cytometric analysis: anti-CD16/32 (2.4G2), CD4 (RM4-5), CD8␣ (53-6.7), CD25 (PC61), CD11c (M1/70), H-2K q (KH114), H-2K d (34-2-12) , CTLA-4 (UC10-4B9), GITR (DTA-1), CD27 (LG.7F9), CD103 (2E7), CD62L (MEL-14), CCR7 (4B12), all antibodies from BD Pharmingen (San Diego, CA), and eBiosciences (San Diego, CA), rabbit anti-mouse CCR4 (Novus Biologicals, Littleton, CO), secondary anti-rabbit FITC (Santa Cruz Biotechnology, Santa Cruz, CA), CCR5 (HM-CCR5) (BioLegend, San Diego, CA). Foxp3 staining was performed using the intracellular Foxp3 staining kit (antibody: FJK-16s) as described in the protocol (eBiosciences). Staining was performed in the presence of purified anti-CD16/32 at saturation to block nonspecific staining. Propidium iodide (Sigma-Aldrich, St Louis, MO) was added before analysis to exclude dead cells. For Phospho flow analysis, the following antibodies were used: phycoerythrin (PE) anti-phosStat5 (pY694, clone 47, 611964; BD Biosciences Pharmingen, San Diego, CA), anti-phospho-p70S6 kinase (Thr421/Ser424, rabbit), anti-phospho-4E-BP1 (236B4, rabbit, both Cell Signaling Technology, Danvers, MA) with secondary goat-antirabbit PE (Jackson ImmunoResearch Laboratories, West Grove, PA). Cells were lysed and fixed with 1ϫ PhosphoFlow Lyse/Fix Buffer for 15 minutes at 37°C, then permeabilized with PhosFlow Perm Buffer III on ice for 1 hour (all Phosflow reagents from BD Biosciences) as described previously. 14 
Immunosuppressive treatment
For in vivo studies, RAPA (Wyeth-Ayerst, Princeton, NJ) was dissolved in carboxymethylcellulose sodium salt (C-5013; Sigma-Aldrich) and polysorbate 80 (P-8074; Sigma-Aldrich). RAPA stock solution was stored at 4°C in the dark in distilled water according to the manufacturer's instructions. Intraperitoneal injections were given once daily and started on d0. Dosage was adjusted to the body weight every other day. The RAPA dosage employed in vivo of 0.5 or 1.5 mg/kg per day corresponds to blood levels that were reported to reach 6 to 15 ng/mL. 15 Immunosuppressive treatment was continued until death or end of the observation period (day 100).
Western blot analysis
T cells that were isolated from in vitro cultures with or without RAPA were counted and resuspended in an appropriate volume (10 L/10 6 cells) of radioimmunoprecipitation assay buffer (Sigma-Aldrich). Proteinase inhibitor cocktail (BD Pharmingen) and phosphatase inhibitor cocktail (Pierce Chemical, Rockford, IL) were included in the lysis buffer. After 45 minutes' incubation on ice, the sample viscosity was decreased by centrifuging through a QiaShredder column (QIAGEN, Valencia, CA). The concentration of proteins in each sample was determined using a BCA assay kit (Pierce Chemical). Each protein sample was suspended in sodium dodecyl sulfate (SDS) sample buffer (4ϫ buffer; Invitrogen, Carlsbad, CA) and subjected to SDS-polyacrylamide gel electrophoresis (PAGE) electrophoresis using precast Tris-HCl Ready-Gels (4%-12%; Invitrogen). Proteins were transferred to polyvinylidene diflouride membranes (Millipore, Temecula, CA) and immunoblotting was performed using conventional methods. The following primary antibodies were used: anti-PTEN (Y184; Abcam, Cambridge, MA), anti-p70S6 kinase (49D7), anti-4E-BP-1 (236B4), anti-mTOR (7C10) antibodies (Cell Signaling Technology).
aGVHD model
Acute GVHD was induced as described previously. 3 In brief, recipients were exposed to lethal irradiation with 800 cGy on day 0 followed by intravenous injection of 5 ϫ 10 6 TCD-BM cells after. To induce aGVHD 1.6 ϫ 10 6 or 10 6 CD4 ϩ /CD8 ϩ T cells in the FVB/N3BALB/c or C57BL/ 63BALB/c model, respectively, were injected intravenously on day 2. Tregs were derived from donors of the same genetic background as the conventional donor T cells and injected intravenously on day 0 at the dosage indicated for the respective experiment. To track Treg/Tconv expansion 5 ϫ 10 5 Treg or Tconv from luc ϩ C57BL/6 donors were given where indicated. Mice were fed antibiotic water (sulfamethoxazoletrimethoprim; Schein Pharmaceuticals, Dartmore, CT).
In vivo bioluminescence imaging
In vivo bioluminescence imaging (BLI) was performed as described previously. 16 In brief, mice were injected intraperitoneally with luciferin (10 g/g of body weight, intraperitoneally). Ten minutes later, mice were imaged using an IVIS200 charge-coupled device (CCD) imaging system (Xenogen, Alameda, CA) for 5 minutes. Imaging data were analyzed and quantified with Living Image Software (Xenogen, Alameda, CA) and IgorProCarbon (WaveMetrics, Lake Oswego, OR).
Histopathology
Tissues were fixed with 10% formalin and embedded in paraffin, and sections of 5 m thickness were mounted on positively charged precleaned microscope slides (Superfrost/Plus; Fisher Scientific, Hampton, NH). Hematoxylin/eosin staining of paraffin-embedded tissue sections was performed according to standard protocols. Evaluation of the stained tissue sections was performed on a Nikon microscope (Eclipse TE 300; Nikon, Melville, NY). Standard magnifications were 200ϫ/0.45 NA and 400ϫ/ 0.60 NA. Microscopic photos were obtained using a Spot digital camera (Diagnostic Instruments, Sterling Heights, MI). Histopathology scoring was performed by an experienced pathologist (N.K.) in a blinded fashion according to a previously published system. 17 
Cell isolation and sorting
Single cell-suspensions from cervical lymph nodes, axillary lymph nodes, inguinal lymph nodes, mesenteric lymph nodes, and spleens were enriched for CD25 ϩ cells after sequential staining with anti-CD25 PE (BD PharMingen) and anti-PE magnetic beads using the autoMACS system (Miltenyi Biotec, Auburn, CA). CD25 ϩ cells were then stained with anti-CD4 APC and sorted on a MoFlow cell sorter (BD Biosciences, Mountain View, CA) for the CD25 high population (15%-20% of the enriched CD25 ϩ cells). This sorting strategy yielded at least 96% CD4 ϩ CD25 ϩ Foxp3 ϩ cells.
T cell-depleted bone marrow (TCD BM) was obtained through negative depletion using anti-CD4 and anti-CD8 magnetic beads (Miltenyi Biotech). For transplantation of conventional and luc ϩ T-cell subsets, splenic single-cell suspensions from FVB-L2G85 mice were enriched with CD4/ CD8-conjugated magnetic beads using the AutoMACS system (Miltenyi Biotech). After enrichment, CD4 ϩ and CD8 ϩ T cells reached more than 90% purity.
Proliferation assay
CD4 ϩ CD25 Ϫ and CD4 ϩ CD25 high T cells from luciferase transgenic animals were cultured in flat-bottomed, 96-well plates and stimulated when indicated with 2 or 5 g/mL each of ␣CD3 (clone 145-2C11; BD Biosciences) and ␣CD28 (clone 37.51; BD Biosciences), IL-2 (100 IU/mL), at a concentration of 2 ϫ 10 5 cells/well. Rapamycin (SigmaAldrich) was dissolved in DMSO (Sigma-Aldrich) and added at the concentrations of 10 ng/mL or 100 ng/mL when indicated. Culture medium consisted of RPMI 1640 supplemented with L-glutamine (2 mM), penicillin (100 U/mL), streptomycin (0.1 mg/mL), 2-mercaptoethanol (5 ϫ 10 Ϫ5 M), and 10% fetal calf serum. After 48 hours cultured T cells were analyzed by BLI or harvested and analyzed by FACS or Western blot. For studies on Treg/Tconv expansion, cells from wild-type (wt) and PTEN Ϫ/Ϫ donors were used as indicated for the respective experiments. Expansion of luciferase transgenic T cells was quantified by adding 6 g/mL luciferin per well. Five minutes later the 96-well plate was imaged using an IVIS200 CCD imaging system (Xenogen) for 2 minutes. Expansion is quantified in photons per second per square centimeter.
Mixed leukocyte reaction for Treg suppressor function
Tregs (CD4 ϩ CD25 highϩ H-2k bϩ Thy-1.1 ϩ ) were incubated for 96 hours with ␥-irradiated (30 Gy) antigen-presenting cells (APCs) (CD11c ϩ H-2k dϩ ), and CFSE ϩ -labeled conventional T (Tconv)-cells (CD4 ϩ CD25 Ϫ H-k2 bϩ Thy-1.2 ϩ ) each population 2 ϫ 10 5 cells. Cell division was monitored by levels of CFSE dilution or thymidine incorporation. Cultures were evaluated in triplicate in 96-well flat-bottomed plates in a total volume of 200 L.
Generation of animals with PTEN ؊/؊ CD4 T cells
As PTEN deficiency results in embryonic lethality, we generated mice with targeted deletion of PTEN specific to the T-cell compartment. Mice homozygous for the Pten flox allele were crossed with Lck Cre transgenic mice (both C57BL/6). Resulting F1 litters had PTEN-deficient T cells, which results in the development of T-cell lymphomas by the age of 10 to 12 weeks 18 ; therefore, animals were killed before that age. C57BL/6 littermate wt mice were used for control studies.
Adoptive transfer of CFSE labeled wt versus PTEN ؊/؊ Tregs
For in vivo cell proliferation analysis, Tregs (10 6 /mL) isolated from wt or PTEN-deficient donor animals were resuspended in plain phosphatebuffered saline (PBS) and stained with Vybrant carboxyfluorescein diacetate (CFSE), succinimidyl ester tracer kit (Invitrogen) at a final concentration of 5 M for exactly 6 minutes at 37°C. Immediately after staining, cells were washed in 5 volumes of ice-cold RPMI plus 10% fetal bovine serum (Invitrogen) twice, resuspended in PBS, and counted before intravenous injection into BALB/c mice that had received irradiation with 800 rad and were transplanted with T cell-depleted bone marrow (TCD-BM). On day 3 after transfer donor type (H-2k b ), Tregs were analyzed by fluorescence-activated cell sorting (FACS) for CFSE dilution or phospho-flow analysis.
Statistical analysis
Differences in animal survival (Kaplan-Meier survival curves) were analyzed by log-rank test. Differences in proliferation of luc transgenic T cells in vitro or in vivo MFI, histopathology scores, V␤ usage, numbers of CD4 and CD8 H-2k q cells were analyzed using the 2-tailed Student t test. Error bars indicate the standard deviation from the geometric mean. A P value less than .05 was considered statistically significant. 
Rapamycin inhibited Treg and Tconv in vitro expansion differentially and allows for the maintenance of high Foxp3 protein expression and suppressor function
To investigate whether the observed synergistic in vivo effects of RAPA and Tregs were based on expansion differences, we exposed luciferase transgenic Tregs and Tconv to CD3/CD28 stimulation in the presence of IL-2. Tregs proliferated less than Tconv, which is compatible with their hyporesponsive phenotype in vitro ( Figure  3A) . Addition of RAPA to the culture resulted in a greater reduction of signal intensity on expanding luciferase transgenic Tconv (CD4 ϩ CD25 Ϫ ) compared with Tregs (CD4 ϩ CD25 high ) with 73 (Ϯ 6%) versus 32% (Ϯ 3%) (P ϭ .012) at 10 ng/mL RAPA and 99% (Ϯ 7%) versus 61% (Ϯ 3%) (P ϭ .014) at 100 ng/mL RAPA signal reduction, respectively ( Figure 3A) . To further delineate the influence of RAPA on Foxp3 expression and Treg suppressor function, Tregs that had been exposed to RAPA for different timepoints were analyzed by FACS ( Figure 3B ) or used in functional assays ( Figure 3D ). We found that Foxp3 expression declined in activation cultures in the absence of RAPA, possibly due to an overgrowth of conventional T cells with more vigorous expansion kinetics in response to CD3/CD28 stimulation compared with Tregs. The decline of Foxp3 protein expression was prevented by the addition of RAPA to the activation culture ( Figure 3B,C) . A representative flow-cytometric analysis for Foxp3 expression on day 6 is shown in Figure 3C . Treg cells isolated from RAPAcontaining cultures displayed increased suppressor activity compared with Tregs cultured in the absence of RAPA when used as suppressor cells against allo-Ag driven T-cell proliferation ( Figure 3C ).
In vivo expansion of Tconv and Tregs with and without RAPA
To evaluate the impact of RAPA on Tconv and Tregs in vivo we used a dosage of 1.5 mg/kg of body weight that has previously been demonstrated to reduce T-cell expansion after aHCT. 3 We transferred luc ϩ Tconv or luc ϩ Tregs (H-2k b ) with TCD-BM into irradiated BALB/c recipients. The signal derived from proliferating luc ϩ Tconv projecting over secondary lymphoid and GVHD target organs was reduced by addition of RAPA compared with PBS ( Figure 4A , first versus second group of 5 animals from left). Conversely, expansion of Tregs was only minimally affected, with no significant overall reduction when measuring the amount of emitted photons/mouse/total body area ( Figure 4B ). Consistent with comparable expansion kinetics assessed by in vivo bioluminescence, equal numbers of donor type CD4 ϩ Foxp3 ϩ cells were detected in peripheral lymph nodes and spleen. A representative FACS analysis is shown for CD4 ϩ Foxp3 ϩ cells isolated from the spleen on day 22 after transplantation ( Figure 4C ). These data are consistent with our observation that in vitro mTOR inhibition during activation is compatible with high Foxp3 expression.
To evaluate the impact of RAPA on surface marker expression relevant for regulatory activity, we investigated expression of CTLA-4, 19,20 GITR, 21, 22 and CD27 23, 24 as well as the homing molecules CD62L, CD103, CCR4, CCR5, and CCR7, several of which have been described to be relevant for Tregϩmediated aGVHD protection. [25] [26] [27] Comparison of the MFI for these surface markers demonstrated that in vivo administration of RAPA did not interfere with a regulatory phenotype or homing molecule expression ( Figure 4D ). We found an increased expression of GITR and CTLA-4 on the surface of donor type Tregs as measured in MFI on day 5 after BMT when additional Tconv cells were given on day 2 compared with the absence of Tconv (data not shown). This increase was independent of the presence or absence of 1.5 mg/kg RAPA.
To further analyze the impact of RAPA on the T-cell receptor (TCR) V␤ usage by Tregs that expand in allogeneic recipients, donor-derived Tregs were isolated from secondary lymphoid organs on day 30 after aHCT. V␤ usage was quantified by FACS analysis ( Figure 4E ). Daily administration of RAPA did not interfere with the polyclonal expansion of donor-type Tregs after transplantation. For personal use only. at STANFORD UNIV MED CTR on January 17, 2008. www.bloodjournal.org From
Differential AKT/mTOR pathway activity in Tregs and Tconv
To investigate the relevance of the mTOR pathway for Tconv and Treg activation after allogeneic stimulation, cells were exposed to ␥-irradiated (30 Gy) allogeneic APC and/or IL-2 and the phosphorylation of mTOR downstream products and STAT5 were quantified. STAT5 was chosen because signaling through the IL-2 receptor activates the STAT5 pathway and based on its previously reported relevance for Treg development. 12 We used flow cytometry to analyze phosphorylation events relevant to intracellular signaling cascades as described previously. 14,28 p70S6 and 4-EBP1 are direct targets of mTOR and their phosphorylation status is a parameter for mTOR activity. 29 Phosphorylation of both mTOR downstream products p70S6 and 4E-BP1 after 48-h stimulation with IL-2 increased significantly in Tconv but less so in Treg cells ( Figure 5A ), indicating a minimal usage of the mTOR pathway by Treg. Conversely, Treg preferentially responded to the activation via STAT5 phosphorylation ( Figure 5A ). Naive Tregs expressed higher amounts of mTOR and p70S6 protein and slightly less 4-EBP1 protein compared with their CD4 ϩ CD25 Ϫ counterparts ( Figure 5B ). Addition of RAPA to the allo-Ag/IL-2 activation culture led to an abrogation of mTOR downstream product phosphorylation in Tconv, whereas the low baseline phosphorylation of these products in Tregs was minimally affected ( Figure 5C ). It is noteworthy that phosphorylation of STAT5 was equally high in the presence or absence of RAPA in Tregs ( Figure 5C ) suggesting a preferential usage of this pathway and possibly referring a relative resistance to mTOR inhibition and increasing activity of the IL-2R/STAT5/Foxp3 pathway.
PTEN expression predicted mTOR susceptibility
PTEN, a phosphoinositol 3,4,5-triphosphatase, catalyzes the reverse reaction of PI3K, thereby negatively regulating the activation of the mTOR downstream signaling pathway. 11 PTEN expression was equal in naive Tregs and Tconv as assessed by flow cytometry ( Figure 6A ) and Western blot analysis ( Figure 6B ). It is noteworthy that PTEN expression decreased when Tconv were stimulated with IL-2, whereas Tregs maintained a constant level of PTEN expression ( Figure 6A ). To investigate the role of PTEN in Tregs, we generated mice with thymocytes that constitutively lack PTEN by crossing transgenic mouse lines that express the Cre recombinase under the control of the distal promoter of the mouse Lck gene 30 with mice homozygous for the Pten flox allele both on the C57BL/6 background. CD4 ϩ T cells isolated from these mice displayed no expression of PTEN compared with wt or heterozygous control animals ( Figure 6C ). To investigate the relevance of PTEN on the expansion kinetics of CFSE-labeled Treg, wild-type or PTEN Ϫ/Ϫ animals were used as Treg donors based on previous studies indicating a critical role for PTEN in regulating Treg proliferation 
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ZEISER 31 The proliferation advantage of Tregs in the presence of RAPA was abrogated when PTEN Ϫ/Ϫ donors were used ( Figure 6D ), indicating that PTEN was involved in the altered PI3K signaling in Tregs compared with Tconv. These data indicate that intact PTEN expression in wild-type Tregs accounted, at least in part, for the reduced signaling through the PI3K/mTOR pathway and thereby decreased susceptibility to RAPA. When comparing the amount of Phos-p70S6 and Phos-4E-BP1 in response to IL-2, we found that PTEN Ϫ/Ϫ Treg displayed significantly more phosphorylated mTOR downstream products (*P Ͻ .01) than their wildtype counterparts ( Figure 7A ). Conversely, when RAPA was present in the culture, the amount of Phos-p70S6 and Phos-4E-BP1 decreased significantly in PTEN Ϫ/Ϫ Tregs (*P Ͻ .01) and was not different from the level of wt Tregs ( Figure 7A ).
To further study the relevance of the observed in vitro effects of PTEN deficiency on Treg expansion in an in vivo situation, we used CFSE-labeled wt or PTEN Ϫ/Ϫ Tregs (C57BL/6) that were given on day 0 of BMT. Interestingly, the percentage of dividing donor type (H-2kb ϩ ) Tregs was higher in PTEN Ϫ/Ϫ donors compared with wt donors (44% vs 19.6%, P Ͻ .05) ( Figure 7B bottom panel) . Treatment of the recipients with RAPA antagonized increased expansion of PTEN Ϫ/Ϫ Tregs, which demonstrated the central role of PTEN for the susceptibility to RAPA (Figure 7B bottom panel) . This was paralleled by increased p70S6 phosphorylation in PTEN Ϫ/Ϫ Tregs that expanded in vivo (Figure 7B top panel) . Addition of RAPA did reduce p70S6 phosphorylation in PTEN Ϫ/Ϫ Tregs but did not affect STAT5 phosphorylation ( Figure 7B top panel) . STAT-5 phosphorylation was higher in wt compared with PTEN Ϫ/Ϫ Tregs after adoptive transfer, possibly because of the preferential usage of the mTOR pathway ( Figure 7B top panel) .
Discussion
In this report, we characterized the impact of RAPA on Foxp3 ϩ CD4 ϩ CD25 ϩ Treg biology after aHCT as well as on a molecular level and found important differences compared with its CD4 ϩ CD25 Ϫ Tconv counterparts. We chose RAPA because it was shown to promote TCR-induced T-cell anergy even in the presence of costimulation 32 and allows for induction of operational tolerance. 33 ,34 Furthermore, we have described previously that in vivo RAPA administration was favorable with respect to Treg function compared with other immunosuppressants such as CSA, which inhibited Treg function. 3 A major finding of the present study is that Tregs and RAPA have a synergistic protective effect on aGvHD as a pathologic immune response. We have shown that the combined approach is more potent at reducing the expansion of alloreactive Tconv cells, which translates into reduced GvHD target organ damage as shown by histologic evaluation. We have shown previously that graft-versus-tumor effects are preserved when Tregs are For personal use only. at STANFORD UNIV MED CTR on January 17, 2008. www.bloodjournal.org From combined with Tconv 35 and maintained in the presence of RAPA. 3 A comparable synergism between Tregs and RAPA has been demonstrated in a model of bone marrow graft rejection. 36 Furthermore, recent data indicate that the combination of RAPA with an agonistic CD28 antibody down-modulates GvHD. 37 Based on these findings, we hypothesized that mTOR inhibition has a differential effect on Tregs compared with Tconv. In support of this hypothesis, we observed that high Foxp3 protein expression was different in the presence and absence of RAPA in cultures containing CD4 ϩ CD25 high cells and in vivo expanding Tregs. These observations can be explained by 2 different mechanisms that are not mutually exclusive.
First, RAPA may prevent overgrowth of Foxp3 Ϫ T cells, which is consistent with the observation that Tregs isolated from RAPA-containing cultures were more suppressive than Tregs cultured in the absence of RAPA. These observations are compatible with data, indicating the enrichment of Tregs in a system with OT transgenic CD4 T cells expanded in the presence of RAPA. 38 Second, the in vitro data can be explained by an increased usage of the STAT5 pathway over the PI3K pathway in response to IL-2 and the presence of mTOR inhibition that may skew the differentiation of CD4 ϩ T cells toward a Foxp3-expressing phenotype. This is in line with recent data indicating that STAT5 activation is sufficient to promote the IL-2R␤-dependent development of CD4 ϩ Foxp3 ϩ Tregs 12 and that Stat5a/b directly regulate Foxp3. 39 Because in vitro and in vivo kinetics of Tregs were shown to follow different dynamics, 40 we investigated expansion of luciferase transgenic Tregs in comparison to Tconv in the irradiated host. The expansion kinetics of Tregs in this model are based on proinflammatory cytokines, up-regulation of CD153 on dendritic cells, 41 and lymphopenia developing within the first 7 days after transplantation. Our observation that in vivo expansion was inhibited significantly more in Tconv compared with Tregs when RAPA was injected is compatible with previous reports demonstrating the preferential expansion of human Tregs over Tconv in the presence of RAPA in vitro 42 and more potent apoptosis induction by RAPA in human conventional T cells. 43 Of clinical importance is the observation that Tregs exposed to RAPA after aHCT maintained a polyclonal V␤ TCR usage and lymph node homing molecules that have been demonstrated to be critical for their in vivo function of Tregs. [25] [26] [27] 44 The observation that the transfer of Tconv in addition to TCD-BM leads to an increase of GITR and CTLA-4 on the surface of donor-type Tregs may be due to cytokine release during the alloantigen-driven immune response.
Our previous studies demonstrated a critical role for calcineurindependent IL-2 production for Treg function in protecting against aGvHD during aHCT 3 ; therefore, we aimed to study further the effects of RAPA on conventional CD4 ϩ T cells and Treg cells. IL-2R signaling is primarily mediated through activation of JAK1 and JAK3 with subsequent phosphorylation and activation of STAT5. 45 IL-2R triggering also leads to activation of other signaling pathways, including MAPK and PI3K. Because previous studies have shown that IL-2 primarily induces JAK/STAT signaling rather than PI3K signaling in Tregs, 46, 47 we aimed to investigate the impact of the differential pathway response on the sensitivity to mTOR inhibition.
It is noteworthy that we found that Treg activation by alloantigen and IL-2 led to a preferential activity of the STAT5 pathway and only very little mTOR activity. These findings are compatible with an altered AKT/mTOR signaling in Tregs compared with Tconv. 48 Our data indicate that mTOR inhibition in the presence of IL-2 allowed Tregs to be constantly activated through the STAT5 pathway and promoted their preferential expansion and Foxp3 expression in the presence of RAPA, whereas conventional CD4 T cells were much more affected by RAPA. This notion is consistent with previous data indicating that RAPA-resistant proliferation of CD8 ϩ T-cell clones could be blocked by anti-IL-2 Abs, suggesting that some of the pathways parallel to the PI3K/mTOR pathway, in this case the STAT5 pathway, triggered by IL-2R signaling account for the Ag-driven RAPA resistance. 49 Furthermore, recent data indicate that expression of PTEN is critical for the hyporesponsive phenotype of Treg cells and that Tregs develop normally in mice with a specific deletion of PTEN in the T-cell compartment. 31 These findings prompted us to analyze the relevance of PTEN for the relative resistance of Tregs toward mTOR inhibition. Although expression levels of PTEN were equal in naive cells, activation induced a rapid down-regulation of PTEN in Tconv but not in Treg cells. The physiologic relevance of this finding may be that Tconv down-regulate PTEN, as a negative regulator of T-cell expansion, when they are activated. By negatively regulating TCR signals, PTEN has been shown to impose a requirement for CD28 costimulation, defining an important mechanism for its role in self-tolerance. 50 Our finding that PTEN deficiency was associated with a reversal of the relative resistance of Tregs toward mTOR inhibition is compatible with data from different tumor models in which PTEN knockdown sensitizes established tumors to RAPA in vitro and in vivo. 51 In conclusion, our data indicate that Tregs and Tconv display differential expansion kinetics when exposed to RAPA. We identified a relative resistance toward RAPA in Tregs based on reduced usage of the mTOR pathway and on functional PTEN. The finding that mTOR inhibition has differential effects on Tregs and Tconv may help to understand the synergistic effect of RAPA and Tregs in aGvHD protection, which has important implications when using Tregs in clinical trials. 
